The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While https://saulezbv680127.wikijm.com/1998254/glp_3_retatrutide_a_comparative_analysis